BioMedNewsBreaks Archive - Page 59 of 251

MondaySep 30, 2024 10:52 am

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO Joins Expert Panel at Long COVID, RECOVER TLC Workshop

Tonix Pharmaceuticals (NASDAQ: TNXP) CEO Seth Lederman, MD, participated at a recent event hosted by the Foundation for the National Institutes of Health (“FNIH”) and the National Institute of Allergy and Infectious Diseases (“NIAID”). According to an announcement from the fully integrated biopharmaceutical company, Lederman was a panel member at the “RECOVER Treating Long COVID – Navigating the Pathway Forward” workshop, which was held last week in Bethesda, Maryland. During the panel, experts discussed clinical trial endpoints that could provide meaningful data to support regulatory approval of potential Long COVID therapeutics. “We were honored to be invited to participate in the Long…

MondaySep 30, 2024 10:30 am

BioMedNewsBreaks — NanoViricides Inc. (NYSE American: NNVC) Announces Filing of Fiscal 2024 Form 10-K

NanoViricides (NYSE American: NNVC), a development-stage company that is creating special purpose nanomaterials for antiviral therapy, filed its Annual Report on Form 10-K for the fiscal year ended June 30, 2024, on September 27, 2024. The company reported cash and cash equivalents of $4.97 million, approximately $7.5 million in Net Property and Equipment (“P&E”) assets (after depreciation), and total current liabilities of approximately $1.36 million as of June 30, 2024. During fiscal 2024, the company utilized net cash of approximately $6.31 million for operating activities, including certain expenditures for Phase 1a/1b clinical trial of NV-387 and drug manufacturing costs for…

FridaySep 27, 2024 10:34 am

BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO), Science of Longevity Featured in Upcoming Episode of “Health Uncensored with Dr. Drew”

Telomir Pharmaceuticals (NASDAQ: TELO), a preclinical-stage biotechnology company seeking to lead developments in longevity science through the treatment of age-related conditions, will be spotlighted during the upcoming episode of “Health Uncensored with Dr. Drew.” The show will be broadcast on Fox Business Network at 5:30 p.m. EST on Sept. 29, 2024. Dr. Drew will talk with Telomir Pharmaceuticals special advisor Dr. Michael F. Roizen, MD, about the science of longevity and the importance that telomeres, or the protective end caps of chromosomes, have on the aging process. During the episode, Roizen will explain how TELO’s Telomir-1-a novel small molecule has…

ThursdaySep 26, 2024 10:40 am

BioMedNewsBreaks — NanoViricides Inc. (NYSE American: NNVC) Announces Execution of MoU Agreement with TheraCour Pharma

NanoViricides (NYSE American: NNVC), a development-stage company that is creating special purpose nanomaterials for antiviral therapy, today announced that it has executed a broad Memorandum of Understanding (“MoU”) agreement with TheraCour Pharma Inc., an R&D firm, signed on September 23, 2024. As a result, the company has now obtained a right of first refusal (“ROFR”) for all antiviral drug developments from TheraCour. According to the announcement, the MoU encompasses all antiviral drug developments and is a crucial step that provides NanoViricides with certain intellectual property rights for developing treatments against any viral infections. The announcement noted that the MoU enables…

WednesdaySep 25, 2024 11:10 am

BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) Announces Newly Opened London-Based ACHIEVE UK Trial Site Amid ‘Very Positive’ Study Progression

TC BioPharm (NASDAQ: TCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies for cancer and other indications, is announcing Guys and St. Thomas Hospital, a London-based hospital with a leading oncology clinic and cell therapy clinical team, as a new site in the ACHIEVE UK Trial. The site opened in September 2024, expediting the progression of the trial timelines and increasing the velocity of enrollment. The ACHIEVE UK clinical trial is an open-label, Phase 2 study evaluating the efficacy and effectiveness of TCB008 in patients with AML or MDS/AML, with either refractory or relapsed disease. “The progression…

TuesdaySep 24, 2024 2:55 pm

BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Featured at Next Month’s NYC ThinkEquity Conference

TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, will be presenting at the ThinkEquity Conference held on Oct. 30, 2024, in New York City. According to the announcement, TC Biopharm CEO Bryan Kobel will be presenting at the conference. During his presentation, Kobel will provide an overview of the company's clinical trials along with recent improvements to TC BioPharm's balance sheet. Hosted by ThinkEquity, a boutique investment bank, the ThinkEquity Conference is a premier showcase of private and public emerging growth companies from all over the world. To view the…

TuesdaySep 24, 2024 12:29 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Industry Expert, Pioneer as New Chief AI Scientist

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, has appointed a new chief artificial intelligence (“AI”) scientist: Lance Myers, PhD. According to the announcement, Myers is the former head of data science at Verily, formerly Google Life Sciences. A renowned industry leader and pioneer in digital health data analytics and body-worn biosensor technologies, Myers is a globally respected authority on utilizing AI in biosensor tech. In his new position, Myers will drive innovation and strategic growth for HeartBeam as the company looks to fully leverage its AI…

TuesdaySep 24, 2024 10:00 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Receipt of Notice of Allowance for China Patent Application Covering AVERSA(TM) Technology

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is announcing that its patent application, which protects its AVERSA(TM) abuse deterrent transdermal technology, has been allowed in China. This follows the receipt of a Notice of Allowance from the Chinese National Intellectual Property Administration (“CNIPA”) for the application entitled “Abuse and Misuse Deterrent Transdermal Systems.” The latest allowance expands the company’s international intellectual property portfolio, which now includes patents issued in 46 countries: Australia, Canada, China, Europe, Japan, Korea, Mexico, Russia, the U.S., and more. To view the full press release, visit https://ibn.fm/3khUt About Nutriband Inc.…

MondaySep 23, 2024 11:20 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that CEO John Climaco will present at the 24th Annual Biotech in Europe Forum. The presentation is scheduled for Wednesday, September 25, 2024, at 1:55 p.m. CEST in Basel, Switzerland. Additionally, management will participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To view the full press release, visit https://ibn.fm/P0zd8 About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing…

MondaySep 23, 2024 10:46 am

BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Completes ACHIEVE Trial Full-Dose Regimen for First Patient

TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, has announced a key step in its ACHIEVE clinical trial. According to the announcement, the first patient has completed the full-dose regimen in the phase 2b trial. In addition, the company announced that six patients have received a second dose and three patients have received a third dose; patients can receive up to four total doses of TCB under the trial protocol. Furthermore, no TCB008-related adverse events have been observed in any of the restart patients. To view the full press release, visit…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO Joins Expert Panel at Long COVID, RECOVER TLC Workshop

BioMedNewsBreaks — NanoViricides Inc. (NYSE American: NNVC) Announces Filing of Fiscal 2024 Form 10-K

BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO), Science of Longevity Featured in Upcoming Episode of “Health Uncensored with Dr. Drew”

BioMedNewsBreaks — NanoViricides Inc. (NYSE American: NNVC) Announces Execution of MoU Agreement with TheraCour Pharma

BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) Announces Newly Opened London-Based ACHIEVE UK Trial Site Amid ‘Very Positive’ Study Progression

BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Featured at Next Month’s NYC ThinkEquity Conference

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Industry Expert, Pioneer as New Chief AI Scientist

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Receipt of Notice of Allowance for China Patent Application Covering AVERSA(TM) Technology

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum

BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Completes ACHIEVE Trial Full-Dose Regimen for First Patient

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search